A new order from the Spanish Ministry of Health updates the medicines reference price system and is expected to result in substantial financial savings
The UK’s standalone accelerated pathway for faster approval and value assessment of medicines is now open to early adopters - six months ahead of schedule
Italy’s Agency for Medicines (AIFA) has approved updated rules for its organisation and staffing, aiming to streamline medicine access and ensure financial sustainability and patient safety
Pharmaceutical companies now have an extra month to decide on their participation in the 2026 voluntary pricing scheme, giving them more time to weigh its financial implications against the less predictable Statutory Scheme.
The Italian Medicines Agency's latest expenditure report reveals a significant overspend on medicines for the first third of the year, driven primarily by costs for new cancer drugs and cardiovascular therapies.
A new strategic plan will see NICE overhaul its processes for evaluating health technology, update guidance dynamically to ensure value, and work in parallel with the MHRA to bring new medicines to patients up to six months sooner.
A new enabling act provides a "once-in-a-generation" opportunity to reform Italy's pharmaceutical legislation, with a focus on tackling regional access delays and preparing for high-cost gene therapies.
Germany's Federal Joint Committee has clarified how it will use new European-level clinical assessments as the foundation for its national drug pricing and reimbursement decisions, confirming that it will retain final authority on a drug's added benefit.
Germany's Institute for Quality and Efficiency in Health Care (IQWiG) is taking part in the first joint health technology assessments (HTAs) at the European level.
